Percheron inks global deal for HMBD-002 cancer drug

Percheron Therapeutics CEO Dr. James Garner talked with Proactive about the company’s newly signed global exclusive license agreement with Hummingbird Bioscience. This agreement allows Percheron to develop, manufacture, and commercialize HMBD-002, an immuno-oncology drug candidate aimed at treating multiple types of cancer globally.

During the discussion, Dr. Graham highlighted the transformative potential of the partnership and the extensive groundwork already laid by Hummingbird, noting the significance of advancing HMBD-002 into later-stage clinical trials and towards commercialisation.

The terms of the agreement include an upfront payment of US$3 million and potential milestone payments of up to US$287 million, reflecting Percheron’s confidence in the drug’s long-term prospects. Dr. Graham emphasised that Hummingbird selected Percheron due to its clinical development expertise and commercialisation readiness.

Looking ahead, Dr. Graham outlined key near-term milestones that investors should monitor as the new financial year begins, with the company focused on pushing forward through the clinical development pathway.

For more updates on this and other biotech stories, head over to Proactive's YouTube channel. Don’t forget to like this video, subscribe to our channel, and turn on notifications so you never miss an update.

#PercheronTherapeutics #HMBD002 #CancerTreatment #BiotechNews #ImmunoOncology #ClinicalTrials #PharmaUpdates #OncologyResearch #BiotechInvesting #HummingbirdBioscience